Outlook Therapeutics, Inc.
Financial highlights
| Metric | FY 09/30/25 | FY 09/30/24 | FY 09/30/23 | FY 09/30/22 | FY 09/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.4M | — | — | — | — |
| Cost of revenue | $1.4M | — | — | — | — |
| Gross profit | $57,205 | — | — | — | — |
| Selling, general & administrative | $39.9M | $29.9M | — | — | — |
| Research and development | $27.2M | $41.8M | $26.5M | $42.3M | $39.0M |
| Operating expenses | — | — | — | — | $51.7M |
| Operating income | -$67.1M | -$71.7M | -$53.1M | -$63.1M | -$51.7M |
| Interest expense | — | $3.2M | $2.5M | — | — |
| Pretax income | -$64.0M | -$75.4M | -$59.0M | -$66.0M | -$53.2M |
| Income tax expense | -$1.6M | $2,800 | $2,800 | $2,800 | $2,000 |
| Net income | -$62.4M | -$75.4M | -$59.0M | -$66.1M | -$53.2M |
| Balance Sheet | |||||
| Cash and equivalents | $8.1M | $14.9M | $23.4M | $17.4M | $14.5M |
| Current assets | $17.4M | $27.4M | $31.0M | $27.5M | $21.5M |
| Total assets | $18.6M | $28.8M | $32.3M | $28.5M | $22.8M |
| Current liabilities | $45.8M | $42.6M | $46.7M | $19.7M | $6.8M |
| Total liabilities | $50.8M | $101.9M | $46.7M | $19.8M | $18.2M |
| Total debt | — | — | $35.6M | $11.1M | $11.8M |
| Stockholders' equity | -$32.2M | -$73.1M | -$14.4M | $8.7M | $4.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$51.8M | -$68.8M | -$43.0M | -$56.7M | -$54.3M |
| Depreciation and amortization | $117,052 | $113,859 | $44,188 | $163,625 | $163,624 |
| Stock-based compensation | $8.9M | $5.4M | $5.5M | $7.7M | $4.9M |
| Dividends paid | — | $0 | $0 | — | — |
Shares outstanding 120.9M · Free float 45.7%
Annual filing data through FY ended September 30, 2025; float as of July 14, 2026.